RxDoctor Payments Data

Ruby Turner

Family · Germantown, TNNPI 1821069733

Payments from drug & device makers

$1,245in general payments, 2019–2025

Across 58 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$152
  • Rigel Pharmaceuticals, Inc.$129
  • Amgen$120
  • Merck$90
  • Lilly USA, LLC$65
  • Johnson & Johnson$61
  • plus $628 from 21 others

What the payments were for

  • Food & beverage$1,14692%
  • Education$998%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,245 in reported general payments places this provider in the 65th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$1,129
Medicare patients
21
Services billed
55

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol15$15,115
SymbicortBudesonide/Formoterol Fumarate16$3,485
Albuterol Sulfate HfaAlbuterol Sulfate35$816
Metformin Hcl28$371
Amlodipine Besylate50$361
Pantoprazole Sodium13$350
Atorvastatin Calcium35$279
Esomeprazole Magnesium11$214
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav18$194
Rosuvastatin Calcium17$175
Lisinopril23$169
Gabapentin18$159
Omeprazole15$133
Allopurinol24$92
Levothyroxine Sodium13$77

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$51$18,59931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,706 family providers in Tennessee.

Other family in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →